Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

This section has been translated automatically.

Antibiotic with cytostatic application: The insertion into the genetic material causes a breakage of the DNA strands.

Pharmacodynamics (Effect)
This section has been translated automatically.

Bleomycin induces in experimental systems the increased expression of extracellular matrix proteins, especially alpha(I)collagen, fibronectin and decorin. In addition, bleomycin stimulates cytokines that play a role in dermal fibrosis, such as the "monocyte chemoattractant protein-1" (MCP-1 protein) and one of its receptors (CCR-2).

Undesirable effects
This section has been translated automatically.

Cutaneous ADRs: Pruritus, toxic epidermal necrolysis, angioedema, striated and generalized hyperpigmentation, melanodermia factitia, extensive skin sclerosis (see below pseudoscleroderma).

Extracutaneous ADRs: fever (10-25% of patients), hypotonus, pulmonary fibrosis, radiation sensitization.

This section has been translated automatically.

Cisplatin: cumulative nephrotoxicity; G-CSF: increased pulmonary toxicity; methotrexate: increased toxicity; phenytoin: decrease in blood levels; oxygen: prolonged exposure to oxygen (anesthesia) results in increased pulmonary toxicity.

This section has been translated automatically.

  1. Abess A et al (2003) Flagellate hyperpigmentation following intralesional bleomycin treatment of verruca plantaris. Arch Dermatol 139: 337-339
  2. Allen JT et al (1999) Enhanced insulin-like growth factor binding protein-related protein 2 (Connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Cell Mol Biol 21: 693-700
  3. Behrens S et al (1998) Bleomycin-induced PSS-like pseudoscleroderma. Case report and review of the literature. dermatologist 49: 725-729
  4. Katz HI (1998) Guide to adverse treatment interactions for skin, hair, and nail disorders. Lippincott-Raven, Philadelphia, New York, S. 27-28
  5. Sleijfer S (2003) Bleomycin-induced pneumonitis. Chest 120: 617-624
  6. Takagawa S et al (2003) Sustained activation of fibroblast transforming growth factor-beta/Smad signaling in a murine model of scleroderma. J Invest Dermatol 121: 41-50
  7. Van Meerten E, Verweij J, Schellens JH (1995) Antineoplastic agents. Drug interactions of clinical significance. Drug Saf 12: 168-182
  8. Yamamoto T, Nishioka K (2002) Analysis of the effect of halofuginone on bleomycin-induced scleroderma. Rheumatology (Oxford) 41: 594-596
  9. Yamamoto T et al (2001) Mast cell-independent increase of type I collagen expression in experimental scleroderma induced by bleomycin. Arch Dermatol Res 293: 532-536
  10. Yamamoto T, Nishioka K (2002) Animal model of sclerotic skin. V: Increased expression of alpha-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma. Clin Immunol 102: 77-83
  11. Yamamoto T et al (2000) Bleomycin increases steady-state levels of type I collagen, fibronectin and decorin mRNAs in human skin fibroblasts. Arch Dermatol Res 292: 556-561
  12. Yamamoto T, Nishioka K (2003) Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 121: 510-516


Last updated on: 29.10.2020